Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.76 |
| ▸ | CA12 | O43570 | 3/20 | 0.63 |
| ▸ | CA1 | P00915 | 3/20 | 0.63 |
| ▸ | CA2 | P00918 | 3/20 | 0.63 |
| ▸ | CA9 | Q16790 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | IDE | P14735 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.61 |
| ▸ | HLCS | P50747 | 1/20 | 0.58 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.58 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5841368 | 1.00 | TDP1 (0.76) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL18025829 | 1.00 | TDP1 (0.76) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL31621058 | 1.00 | TDP1 (0.76) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL13169001 | 1.00 | TDP1 (0.76) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL19069314 | 1.00 | TDP1 (0.76) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL24750115 | 1.00 | TDP1 (0.76) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL8333056 | 0.98 | TDP1 (0.73) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL24627775 | 0.97 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL18779801 | 0.95 | TDP1 (0.78) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL19960973 | 0.94 | TDP1 (0.74) | TDP1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113956361-B | Antibodies to ticagrelor and methods of use thereof | 免疫医疗有限公司 | 2025-06-17 | — | — | CN | disclosed |
| US-11161884-B2 | Modified biotin, streptavidin mutant, and usage of them | SAVID THERAPEUTICS INC. (JP) | 2021-11-02 | — | — | US | disclosed |
| US-11124549-B2 | — | — | 2021-09-21 | — | — | US | disclosed |
| US-9694086-B2 | HCV protease inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-07-04 | — | — | US | disclosed |
| US-20160243249-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2016-08-25 | — | — | US | disclosed |
| US-5936065-A | PRODRUG AS ANTIINFLAMMATORY AGENT FOR AUTOIMMUNE DISEASES; FOR SUPPRESSING BINDING OF INFLAMMATORY CELLS TO ENDOTHELIAL CELLS THAT EXPRESS THE CS-1 PORTION OF FIBRONECTIN ON THEIR SURFACES | CYTEL CORPORATION (US) | 1999-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124549-B2 | — | BTD, HLCS, BROX | TDP1 4590/4885CA12 4601/4885CA1 4874/4885 |
| US-20160243249-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | TDP1 2867/4885CA12 2068/4885CA1 3888/4885 |
| US-11161884-B2 | Modified biotin, streptavidin mutant, and usage of them | BTD, HLCS, BROX | TDP1 4670/4885CA12 4450/4885CA1 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.